{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "F",
          "alt": "dead",
          "position": "kinase_domain"
        },
        "variant_string_id": "LRRK2 Fkinase-dead"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause dominant Parkinsonâ€™s disease (PD). Patients with LRRK2 mutations show a loss of striatal 18F-DOPA PET signal, consistent with a loss of presynaptic neurons projecting from the substantia nigra pars compacta (SNpc) to the striatum.",
          "judgment": "Yes",
          "reasoning": "The paper establishes that LRRK2 mutations are associated with PD, a neurodegenerative disease characterized by neuronal loss and dysfunction.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Manipulating activity by replacing the kinase domain with a Fkinase-dead version blocks inclusion body formation and strongly delays cell death.",
          "judgment": "Yes",
          "reasoning": "The assay, kinase domain replacement, is relevant to the established disease mechanism of neuronal loss and dysfunction as it directly assesses a functional impact of the mutation on a key cellular phenotype (inclusion body formation and cell death).",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Manipulating activity by replacing the kinase domain with a Fkinase-dead version blocks inclusion body formation and strongly delays cell death.",
          "judgment": "No",
          "reasoning": "The text describes the experiment but does not explicitly mention the inclusion of normal/wild-type controls or specify the number of replicates used.",
          "next_step_or_outcome": "Proceed to Sub-step 1b"
        },
        {
          "step_name": "Sub-step 1b: Accepted/Validated Assay",
          "extracted_paper_info": "The paper does not state whether kinase domain replacement is a novel or validated assay.",
          "judgment": "No",
          "reasoning": "The paper does not provide enough information to confirm accepted or validated status. ",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The observation that replacing the kinase domain with a Fkinase-dead version blocks inclusion body formation and delays cell death provides supporting evidence for the pathogenicity of LRRK2 mutations. While the assay itself appears functional, it lacks clear basic controls or explicit validation, thus assigning a supporting strength rating."
    }
  ]
}